Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

BACKGROUND: The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients. However, these results were obtained in young low risk patients and a reevaluation in an unselect...

Descripción completa

Detalles Bibliográficos
Autores principales: Lisenko, K., Dingeldein, G., Cremer, M., Kriegsmann, M., Ho, A. D., Rieger, M., Witzens-Harig, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440917/
https://www.ncbi.nlm.nih.gov/pubmed/28532396
http://dx.doi.org/10.1186/s12885-017-3332-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440917/
https://www.ncbi.nlm.nih.gov/pubmed/28532396
http://dx.doi.org/10.1186/s12885-017-3332-3

Ejemplares similares